FDA accepts Biologics License Application and grant priority review of aducanumab as treatment of Alzheimer’s disease

Application for this human IgG1 monoclonal antibody selective for fibrillar form of beta amyloid includes data from phase III EMERGE and ENGAGE trials, as well as phase Ib PRIME study. If approved, it would be the first therapy to reduce clinical decline of Alzheimer’s disease.


Biospace Inc.